Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy.

Abstract excerpt

This study aimed to investigate the impact of common polymorphisms in key cytochrome P450 (CYP) genes (CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A5) on drug levels and treatment responses in Plasmodium vivax-infected patients treated with chloroquine (CQ) and primaquine (PQ). CYP2C8 and CYP3A5 are the key enzymes that metabolize CQ, whereas CYP2D6, CYP2C9, and CYP2C19 are those that metabolize PQ. A total of 99...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antimalarials
• Share to Chloroquine